Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI app aims to keep young hearts healthy after hospital discharge

NCT ID NCT07031531

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study is testing whether an AI-driven system called SMART-CHD can improve outcomes for adults aged 18-45 with premature coronary artery disease. Participants will use a mobile app and wearable sensors to track their health and receive personalized guidance. The goal is to see if this approach reduces the risk of death, heart attack, stroke, or rehospitalization compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-Enabled Stratified Management System (SMART-CHD mobile app and paired wearable sensors)
What this could lead to
If successful, this could provide a scalable, personalized way for young heart disease patients to better control risk factors and reduce hospital readmissions.
What could go wrong
This is a relatively early-stage trial without a prior phase, and the intervention relies heavily on patient engagement and technology adherence. Results may not generalize to less tech-savvy populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Patients with coronary heart disease aged 18-45 years; 2. The patient or a close family member is capable of using a smartphone and mobile application (App); 3. Willing to participate in the study and able to provide written informed consent. Exclusion Criteria 1. Severe cognitive impairment; 2. Advanced-stage malignancy; 3. Life expectancy less than 12 months; 4. Severe multi-organ failure; 5. Refusal to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature coronary heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, 518057, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

  • Henan Provincial Chest Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450000, China

  • Northern Jiangsu People's Hospital

    NOT_YET_RECRUITING

    Yangzhou, Jiangsu, 225001, China

  • Shanxi Cardiovascular Disease Hospital

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, 030024, China

  • The Affiliated Hospital of Southwest Medical University

    NOT_YET_RECRUITING

    Luzhou, Sichuan, 400042, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    NOT_YET_RECRUITING

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanjing Medical University

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210029, China

  • The First Affiliated Hospital of University of Science and Technology of China

    NOT_YET_RECRUITING

    Hefei, Anhui, 230001, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, 710061, China

  • The First Hospital of Hebei Medical University

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi'an, Shaanxi, 710004, China

  • The Second Affiliated Hospital, School of Medicine, Zhejiang University

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, 310009, China

  • The Second Hospital Of Hebe Medical University

    NOT_YET_RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • Zhengzhou University Affiliated Zhengzhou Central Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450000, China

  • Zhengzhou University Fuwai Central China Cardiovascular Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.